Medical Ceramics Market Poised to Witness a Significant Growth by 2023

 Medical Ceramics Market Overview

Global medical ceramics market share is growing rapidly. Market growth attributes to the increasing prevalence of cardiovascular disorders and dental & orthopedic issues that create a huge demand for surgical implants, prosthetics, and various medical tools & devices. Also, the rising awareness about the health and availability of new treatment methods drive the growth of the market. Moreover, increasing healthcare expenditures and improving living standards of populaces accelerate market growth.

According to Market Research Future (MRFR), the global medical ceramics market is expected to grow at over 6.5 % CAGR during the assessment period (2017-2023). Rising older population that leads to increasing numbers of dental caries patients and increasing awareness towards dental health is a major factor impacting the market growth excellently.

Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) of Medical Ceramics Market @ https://www.marketresearchfuture.com/sample_request/5729

Also, factors such as government initiatives and support and rising demand for advanced oral and orthopedic treatments are major growth drivers for the market growth. Additionally, increasing numbers of industry players offering newer products, alongside the dentistry growing at an impressive rate, boost the growth of the market.

Medical Ceramics Market Major Players:

Players active in the global medical ceramics market include 

• Zimmer Holdings Inc
• CoorsTek Inc.
• Straumann
• H.C. Starck GmbH
• Stryker
• Kyocera Corporation
• 3M ESPE
• Nobel Biocare Services AG
• DePuy Synthes
• Morgan Advanced Materials

Global Medical Ceramics Market – Segments

The report is segmented into four dynamics;

By Type: Bioinert Ceramics, Bioactive Ceramics, and others.

By Application: Orthopedic, Dental, Plastic Surgery, Diagnostic Instruments, Cardiovascular, and others.

By End-User: Specialty Centers, Hospitals & Clinics, and others.

By Regions: Americas, Europe, Asia Pacific, and the Rest-of-the-World. 

Global Medical Ceramics Market – Regional Analysis

North America leads the global medical ceramics market. The largest market share attributes to the increasing prevalence of cardiovascular disorders and geriatric populaces that need the dental and implants the most. Besides, factors such as the high healthcare expenditure and rising demand for technologically advanced treatments & products drive the regional market growth. Also, the rising government support in the region enhances the medical ceramics market growth in North America.

Europe accounts for the second-leading share in the global medical ceramics market. The market is largely driven by the availability of advanced treatment facilities and increasing research activities in the field of medical ceramics for nanotechnology. Moreover, factors such as the rising cases of dental cavities, rising population awareness regarding health, and increasing per capita healthcare expenses drive the regional market growth. The European medical ceramics market is estimated to create a substantial revenue pocket during the forecast period.

The Asia Pacific medical ceramics market is growing rapidly. Factors such as the massive adoption of ceramics in the medical implant manufacturing industry and rising economic growth in the region foster the regional market growth. China has emerged as the largest manufacturing hub owing to government incentives and the ongoing trade agreements with other countries. The Asia Pacific medical ceramics market is expected to garner the highest growth rate during the review period.

Global Medical Ceramics Market – Competitive Landscape

Highly competitive, the medical ceramics market appears fragmented due to the presence of several players. The industry exhibits characteristics of a bulk low-value high volume product, leading to pricing pressure. As a result, the industry is concentrated in low-cost destinations such as China and Vietnam, compounding pricing pressure issues. However, rising labor costs in China prompted to seek other suitable locations, and India has emerged as an attractive location for manufacturers. 

Industry players are developing close relationships with the end-users to create custom-built products. The integration of clients in the designing phase increases their dependency resulting in stable business revenue. Medical ceramics manufacturers are also using a variety of distributions channels to address market penetration and revenue growth. They acquire high tech firms with proprietary technology so as to gain the position of an industry leader.

Medical Ceramics Industry/ Innovation/ Related News:

May 02, 2020, —- Austrian researchers published their study on lithography-based ceramic manufacturing (LCM), focusing on glass ceramics to optimize applications like dental replacements. The study was published under the title Stereolithographic Additive Manufacturing of High Precision Glass Ceramic Parts.

3D printing often involves the use of ceramics to offer innovative progress in dental and orthodontic labs. It needs the highest level of accuracy to fabricate crowns, bridges, and implants. Moreover, superior mechanical properties are necessary to create aesthetics & the proper fit.  

To achieve this, industry players use different types of 3D printing technologies such as FDM 3D printing, Selective laser sintering (SLS), 3D printing & stereolithography (SLA), and Lithography-based ceramic manufacturing (LCM). Researchers chose LCM, as it allows the creation of highly filled and photopolymerizable ceramic slurries and dense parts comprised of ‘outstanding’ material properties. 

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/medical-ceramics-market-5729

Blood Transfusion Diagnostics Market to Witness an Outstanding Growth by 2023

 Market Research Future published a Half Cooked Research Report on “Global Blood Transfusion Diagnostics Market Research Report-Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.

Ortho Clinical Diagnostics (U.S), Immucor (U.S), Beckman Coulter (U.S),  Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens (Germany), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany),  DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).are some of the prominent players at the forefront of competition in the global Blood Transfusion Diagnostics market and top seven players are profiled in MRFR Analysis. 

Browse Sample of the Report @   https://www.marketresearchfuture.com/sample_request/1126 

Global Blood Transfusion Diagnostics Market   – Overview

Blood transfusion is an essential part of providing healthcare services to the patients. Blood and blood products like RBC’s, WBC’s, platelets and others are transfused from one person to another. This requires screening tests which are vital before conducting blood transfusion. Strict regulation governing the use and transfer of blood, increasing awareness regarding blood transfusion and automation of blood banks drive the growth of this market. Furthermore, increasing demand for diagnostic and treatment devices in developed and developing countries further influence the growth of the market. However, the growth of the market is restrained by various factors such as risk involved in transmission of infectious disease from one person to another without carrying out screening procedure.

Global Blood Transfusion Diagnostics Market   – Competitive Analysis

There is a significant increase in the number of the company offering blood transfusion diagnostics. Some major companies are trying to focus on new and advanced tests & products to gain the market. Whereas, some are has used the technique of acquisition and collaboration to gain the blood transfusion diseases market.

Hoffmann-La Roche AG:

• August, 2015: F. Hoffmann-La Roche AG acquired GeneWEAVE to strengthen offerings in microbiology diagnostics. Roche will pay GeneWEAVE shareholders USD 190 million upfront and up to USD 235 million in contingent product related milestones
• February 2015 : F. Hoffmann-La Roche AG announced the collaboration with BioMed X for the development of Nanomaterial-Based Biosensors for Near-Patient Testing
• September 2014: F. Hoffmann-La Roche AG launched Elecsys anti-Müllerian Hormone (AMH) fertility test for assessment of ovarian reserve for pregnancy

Abbott:

• June, 2017: Alere shareholders approve amended merger with Abbott. This merger will further strengthen the global presence of the company.
• August, 2016: Abbott announced the introduction of its new “Alinity”, a family of next generation systems across immunoassay, clinical chemistry, point of care, haematology, blood and plasma screening and molecular diagnostics.
• April, 2016: The company received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia. The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.
• April, 2016: Abbott received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia. The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.

Bio-Rad Laboratories, Inc.:

July 2017: Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products launched Amplichek I quality control for the testing of infectious diseases.

Global Blood Transfusion Diagnostics Market   – Regional Analysis

Globally, Americas account for the largest market share in blood transfusion diagnostics market consists of two regions namely North America and South America. Increasing in number of blood banks, adoption of automation in blood banks, awareness programs in school & medical institutes and demand of safe and reliable technology for blood transfusion drive this market in North America. Increasing adoption of Nucleic Acid Amplification for diagnosis of blood and blood products also contribute to the growth of this market in North America. United States is the biggest market place worldwide contributing 46% of total blood transfusion diagnostics market. Ortho-Clinical Diagnostic is the largest transfusion diagnostic equipment and solution provider with estimated market share of 7 to 8%. Medical institutes conduct lecture and conference on safe blood transfusion for medical students and also for patients. Europe blood transfusion diagnostics market has observed stable growth owing to increasing demand for advanced diagnostic products. Asia-Pacific is fastest growing market region for this market due to presence of huge patient pool, and huge opportunity for the market growth. The Middle East and Africa holds the least share in the market due to lack of awareness among the people and limited development of medical sector.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market-1126

Global Botulism Illness Market Research Report 2020 Analysis and Forecast to 2023

 Market Research Future adds the “Botulism Illness Market Research Report – Forecast to 2023” report to their unique collection. Botulism Illness Market Is Expected To Grow At A CAGR Of 5.9% During Forecasted Period 2017-2023.

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Botulism Illness Market Research Report – Forecast to 2023” Gives industry size, top players and worldwide demand

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/822

Study objectives global botulism illness market

• To provide detailed information about drivers and factors restraining the market growth.
• To provide the market growth map over the forecasted period 2017-2023
• To provide detailed analysis of the market structure along with forecast for the next seven years of various segments and sub-segments of the global botulism illness
• To provide the graphs and analyze the market on various factors like- Price Analysis, Supply Chain Analysis, Porters Five Force Analysis etc.
• To provide the trends and opportunities in global botulism illness
• To provide historical and forecast revenue of the market segments and sub-segments with respect to main countries
• To provide the overview of key players and their strategic profiles in the market and drawing a competitive landscape for the market

Intended Audience

• Pharmaceutical companies
• Research and Development (R&D) companies
• Independent research laboratories
• Market research and consulting service providers
• Medical research laboratories
• Academic medical institutes and universities

Market scenario:

Botulism illness is one of the rare and fatal paralytic disorders caused by neurotoxins produced by a bacteria Clostridium botulinum. Weakness, feeling tired, trouble in speaking and fever are some of the major symptoms of the disease. Botulism can be spread several different ways and is mainly caused due to food, water and neighbouring environment. The major driving factor for the growth of global botulism illness market are increasing prevalence of botulism, lack of hygiene in certain regions of the world, availability of efficient solutions for botulism and increase in R&D practices. Increasing awareness among the people also contribute to the growth of the market. However, high cost of R&D and long approval time for the drug are some of the hurdles expected to hinder the growth of botulism illness market

Botulism Illness Market share Is Expected To Grow At A CAGR Of 5.9% During Forecasted Period 2017-2023.

 Segmentation

Global botulism illness market is segmented on the basis of type, into botulinum type A and botulinum type B. On the basis of drug type, the market is segmented into antibiotics, antitoxins and others. Antitoxin are further sub segmented into trivalent antitoxin and heptavalent botulinium antitoxin and on the basis end users, the market is segmented into hospital, clinics and other

Regional analysis

On regional basis, America accounts for the largest market of global botulism illness followed by Europe. Well-developed healthcare sector, increasing healthcare expenditure and increasing awareness among the people are the major factors for the growth of the market in America. Asia Pacific is the fastest growing region for the market due to rapid development in the economies and increasing healthcare expenditure.

Key players for global botulism illness market

Allergan Inc. (Ireland), XOMA Corporation (US), Pfizer Inc. (US), AlphaVax, Inc (US), Microbiotix, Inc (US), Molecular Targeting Technologies, Inc (US), Ipsen Technologies Pvt. Ltd (France), Galderma S. A. (Switzerland), Canbex Therapeutics Ltd (US), Azidus (US)

The report for global botulism illness market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/global-botulism-illness-market-822

Atrial Fibrillation Market: Detailed Segmentation and Forecast 2023

 Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Atrial Fibrillation Market Analysis – Forecast Report Till 2023” Gives industry size, top players and worldwide demand

Industry Overview

The worldwide atrial fibrillation market is predicted to grow at a double digit CAGR over the forecast period (2017 to 2023). Atrial fibrillation, also denoted as AF, is an irregular or fast heart rhythm. It raises the dangers of chest pain, heart strokes, congestive heart failure, or cardiac discomfort. The typical indications of AF are dizziness, confusion, fainting, or tiredness.

AF cases within the elderly population, preference for catheter ablation, and escalating technological developments propel the AF market. Atrial fibrillation is a majorly common arrhythmia that results in disturbed cardiac rhythms. In the last twenty years, a higher existence of AF incidences has been witnessed around the globe. The ‘American Heart Association’ stated that about 34 million people were afflicted with AF globally in 2013.

Also, the United States observes approximately 200, 000 to 400, 000 fresh cases every year. Rising AF cases have been the key contributor of this industry. Moreover; diabetics, high-blood pressure patients, and obese people have developed cardiac problems, eventually propelling the industry. Rheumatic fever incidences have seen a rise, driving the atrial fibrillation market from 2017 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5661

Scientists and field experts have been collaborating to come up with innovative technologies for the premature diagnosis of AF. They have also been trying to offer better treatments to AF patients. Both these factors have generated higher demand for AF devices, furthering industry growth. On the other hand, increase in therapeutic expenses and scarcity of proficient doctors hamper the market.

According to a study by ‘Market Research Future’ (MRFR), the global AF market is set to experience decent expansion in the forecast period. Various lifestyle illnesses, poor eating habits, and sedentary occupations may also cause a surge in cardiac issues, leading to some of the AF incidences. All these factors could further contribute to the growth of this industry. Another hindrance for the market comprises the inclination towards pharmaceutical drugs over AF therapeutics.

Classification/Segmentation

The global atrial fibrillation market is divided on the basis of products, end-users, and geographical regions. By products, the industry is fragmented into non-surgical and surgical. The end users consist of cardio centers, big hospitals, and heart specialty care enterprises. Geographical regions into which the market is split, comprise Americas, Europe, Asia Pacific, and the Middle East and Africa.

Catheter ablation, a sub-segment of surgical products, is typically adopted for managing & treating cardiac arrhythmias. It is normally advised for the management of atrial fibrillation when patients can neither tolerate nor be given anti-coagulation drugs. Hence, catheter ablation occupied major shares in 2015. It is reported to be the most rapidly growing sub-segment in the near future.

Modern heart specialty and cardiac centers should witness the maximum adoption of AF devices. In view of geographies, Americas maintains supremacy over the market and would do the same in the forecast period. The usage of high-tech products & services and improved medical infrastructure is accountable for the same. Mexican sellers and government have spent heavy capital on the AF industry.

Asia Pacific will grow at the fastest pace & be driven by its huge patient base and population. Additionally, its need for atrial fibrillation devices can increase owing to better medical infrastructure and high Chinese & Indian healthcare costs.

Worldwide Rivals and Innovative Trends

Some of the well-established players operating in the global market are Biosense Webster, Carima, Agricore, Medtronic, and St. Jude Medical. They focus on new therapies for gaining wide recognition and edge over one another.

Catheter ablation has been further modified to suit patient-needs and offer cutting-edge therapies for AF patients. Majority of the patients across developed nations are treated with catheter pulmonary vein ablation. Such patients do not recover from medicines and have symptomatic AF.      

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/atrial-fibrillation-market-5661

Stem Cell Assay Market – A market with high CAGR and return on investment by 2023

 

Market Insights:

Stem Cells have been acknowledged for their promising potential toward the development of various cutting-edge treatments for a number of diseases. As such, stem cell assays have a rapidly growing market. Stem cell assays are essentially the techniques used for analyzing living cells by various parameters which ultimately help determine the biochemical and cellular functioning of cells. This has immense promise in drug development activities. Market Research Future’s study of the market in its latest report has found that the global stem cell assay market size to register a highly optimistic outlook at a CAGR of 19.80% during the review period from 2017 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5656

Stem cell assays are a promising part of the biotechnology field, which is growing at a rapid pace. The prevalence of chronic and several lifestyle diseases has compelled the growth of drug development activities in an effort to develop effective treatments. Diseases such as cancer and diabetes are soaring at high rates and the demand for better, efficient and more affordable treatments are driving the market toward growth. Healthcare expenditure across the globe is increasing, and advancement in biotechnology and other medical technologies is highly encouraging of market growth. Government support toward drug development for chronic diseases has increased stem cell assay research.

The market is held back by stringent government policies associated with approval of drugs as well as the high procedural cost of stem cell assays. Moreover, there is a lack of awareness regarding stem cell assays, and as a result, there is a dearth of skilled professionals which restrains market growth. However, growing healthcare activities and the increasing demand for treatment is likely to bring stem cell assays to the forefront and opportunities in the market are plentiful.

Market Segmentation:
Market structure is determined by its various significant sections which, in the report have been segmented on the basis of product, technology, assay, application, end-user, and region. Products in the market include flow cytometer, cell imaging systems, automated cell counter, kits, and others. The kits segment has been sub-segmented and includes umbilical cord stem cells, induced pluripotent stem cell kits, mesenchymal stem cell kits, and others.

The technology used in stem cell assays include microfluidics-based cell trap technologies, microfabricated assisted technology, and others

Assays in the market include cell identification assays, cell viability & toxicity assays, cell proliferation assays, cell apoptosis assays, and others.

Applications of stem cell assays can be found in orthopedic & musculoskeletal spine, dermatology, cardiovascular, central nervous system, and others.

End-users of stem cell assays include research organizations, academic institutes, biotechnology industries, academic institutes, and others.

Regional Analysis:
The Americas have captured the dominant share of the global market. The presence of North America in the region has had a significant impact on the regions market share possession. The rapid adoption of advanced medical technologies and the presence of a large patient population for various chronic diseases drive the Americas’ market. Moreover, the regions healthcare expenditure is rising, and there are several leading players present in the North American sub-market.

Meanwhile, growing at the fastest pace is the Asia Pacific regional market. Gradually increasing awareness regarding advanced medical biotechnology is strongly impacting growth in the region. Several emerging economies in the region have a rapidly growing biotechnology sector which fuelling market growth. Findings by the Indian Brand Equity Foundation suggest that the Indian subcontinent has 2% of the global biotechnology share. Several opportunities in the region are expected to lead to market proliferation.

Key Players:
Prominent players included in MRFR’s report are Cell Biolabs, Inc., Thermo Fisher Scientific, Hemogenix, Merck KGaA, Promega Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cellular Dynamics International Inc., STEMCELL Technologies Inc., and others

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/stem-cell-assay-market-5656

Dietary supplements Market Projected to Witness Vigorous Expansion by 2023

 Market Scenario:

Historically, dietary supplements marketing has focused on promoting a specific specialty ingredient targeted at specific consumer health needs such as omega 3 for heart health, lutein for eye care and others. Personalized nutrition offers manufacturers, the chance to develop a relationship with consumers rather than a single transactional approach. Massive advancements in the dietary supplements preparation in the field of personalized nutrition along with the possibility of the superior drug formulation will uplift the U. S. dietary supplements in the age of personalized nutrition market. The economies of scale and scope resulting out of greater demand for dietary supplements is expected to significantly reduce the final price of the products thus benefiting the final consumers. Thus, increasing the prevalence of cancer and metabolic diseases will result in arise in the volume of the dietary supplements market.

Dietary supplements in an age of personalized nutrition is regarded as one of the most noteworthy changes in the healthcare sector because of its capability to provide improved drug delivery and better patient/individual treatment process. Massive advancements in the dietary supplements preparation in the field of personalized nutrition along with the possibility of the superior drug formulation will uplift the U. S. dietary supplements in the age of personalized nutrition market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5644

However, spurious and misbranded products and safety concerns of dietary supplements affect the growth of the U. S. dietary supplements in the age of personalized nutrition market negatively.

The U. S. dietary supplements in the age of personalized nutrition market is expected to grow at a CAGR of 7.95% during the forecast period 2017-2023.

Intended Audience:

• Dietary Supplements Manufacturers
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Segmentation                                                                                                                                      

The U. S. dietary supplements in the age of personalized nutrition market is segmented by product category, application, gender, dosage form and end-user.

By the product category, it is segmented into vitamins, herbs & botanicals, sports supplements, meal supplements, minerals and other.

By the application, it is segmented into lifestyle diseases, inherited diseases, genetic predispositions and others.

By the gender, it is segmented into female and male. Female and male is further segmented into various age groups, namely, 55 + age group, 35-54 age group, 19-34 age group, and 0-18 age group.

By the dosage form, it is segmented into tablets, capsules, powder, liquids, soft gels and others.

By the end-users, it is segmented into hospitals & clinics, home care, and others.

Key Findings

• The U. S. dietary supplements in the age of personalized nutrition market was USD 18,093.1 million in 2016
• Vitamins is the largest segment, by product category which is projected to grow at a CAGR of 8.37% during the forecast period from 2017-2023
• Female is the largest segment, by gender in S. and expected to grow at a rate of CAGR 8.45% during the forecast period
• The tablets segment accounted for the largest market share with 28.3% for the U.S. dietary supplements in the age of personalized nutrition market by dosage and is expected grow with the CAGR of 8.44% for the forecast period.

Key Players                                                                                                         

Some of the key players in this market are Nestlé Health Science, Danone Nutricia, Carlyle Group, Amway (Nutrilite), Archer Daniels Midland, Abbott Laboratories, Herbalife International, Amway, Danisco, Glanbia, Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Balchem Corporation, Natures Product Inc., Bactolac Pharmaceutical Inc. and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/u-s-dietary-supplements-market-5644 

Fertility Services Market – Product Development is the best strategy for market position; Forecast till 2023

 Market Highlights

Global Fertility Services Market size is expected to register a CAGR of 8.99% during the forecast period, with a market value of USD 44,136.91 Million by 2025. Fertility services are procedures or treatments used to cure genetic and fertility issues and assist with conception. These services include assisted reproductive technology (ART) methods and drugs that help infertile couples in planning a family.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6281

Segment Analysis

The Global Fertility Services Market has been segmented by underlying cause and treatment.

Based on the underlying cause, the fertility services market has been segregated into female infertility and male infertility.

The Global Fertility Services Market, based on the treatment, has been segmented into ART and infertility drugs. The ART treatment has been further segmented into in-vitro fertilization (IVF), frozen embryo replacement (FER), artificial insemination, and others.

Regional Analysis

The Global Fertility Services Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Europe is expected to dominate the global fertility services market. This can be attributed to the lower fertility rate in the region and increasing IVF tourism in Spain. For instance, according to the European Society of Human Reproduction and Embryology (ESHRE), Spain is the preferred destination by foreigners for reproductive procedures, representing almost 40% of European fertility tourism, which is estimated to rise in the future. Moreover, easy reimbursement policies and increasing obesity cases are also expected to drive market growth.

The Americas market for fertility services is estimated to be the second-largest during the review period. The high number of ART procedures in the US is expected to boost the growth of the regional market. For instance, as per the data mentioned by the Centers for Disease Control and Prevention, in 2017, nearly 284,385 ART cycles were performed at 448 clinics in the US. Additionally, late pregnancies and the high adoption rate of IVF treatment are further fueling the market growth.

Asia-Pacific is estimated to be the fastest-growing market owing to the declining fertility rates in the region. According to the data suggested by the World Bank, the fertility rate in Japan decreased at a rate of 1.6 in 2016. Moreover, fertility disorders followed by favorable reimbursement scenario is also positively affecting the market growth.

The market in the Middle East & Africa is expected to witness steady growth due to the reduced ovarian reserve in women in the Middle Eastern countries.

Key Findings of the Study

• The Global Fertility Services Market is estimated to reach USD 44,136.91 Million by 2025 at a CAGR of 8.99% during the assessment period
• Europe accounted for the largest share of the global fertility services market due to the low fertility rate and increasing obesity rate
• Based on the underlying cause, the female infertility segment accounted for the largest market share of 5% in 2018
• Based on treatment type, the Assisted Reproductive Technology (ART) segment accounted for the largest market share of 21% in 2018

Key Players

MRFR recognizes the following companies as the Key Players in the Global Fertility Services Market— Merck KGaA (Germany), CooperSurgical, Inc. (US), Care Fertility (UK), Ferring B.V. (Switzerland), INVO Bioscience (US), Vitrolife (Sweden), Monash IVF Group (Australia), Cook (US), FUJIFILM Irvine Scientific (US), and Kitazato Corporation (Japan).

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/fertility-services-market-6281